EdU followed by doxorubicin treatment selectively targets:
Sequential application of EdU labeling followed by doxorubicin treatment represents strategy to track and preferentially eliminate newly dividing cells. EdU pulse marks cells traversing S phase with alkyne-modified nucleotide that persists in DNA of daughter cells, identifiable via click chemistry fluorescent azide. When doxorubicin subsequently administered, antineoplastic action via topoisomerase II trapping and generation of reactive oxygen species is most pronounced in actively cycling population where chromatin decondensed, replication forks active, and topoisomerase IIalpha expression hi
Ref: Thorn et al Doxorubicin S-phase targeting; Salic & Mitchison EdU newly dividing cells detection for chemosensitivity studies.